CGC - Canopy Growth Corporation

NYSE - Nasdaq Real Time Price. Currency in USD
27.74
-1.05 (-3.63%)
As of 10:47AM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close28.79
Open28.63
Bid28.17 x 1000
Ask28.17 x 1000
Day's Range27.71 - 28.75
52 Week Range22.76 - 59.25
Volume1,336,189
Avg. Volume4,691,581
Market Cap9.595B
Beta (3Y Monthly)3.68
PE Ratio (TTM)N/A
EPS (TTM)-1.79
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Canopy Growth Stock Rises, Oppenheimer Initiates Coverage
    Market Realist

    Canopy Growth Stock Rises, Oppenheimer Initiates Coverage

    Oppenheimer analyst Rupesh Parikh initiated coverage on Canopy Growth stock. The analyst gave a “perform” rating with no target price.

  • Barrons.com

    Don’t Buy Canopy Growth Stock. The Marijuana Company Is About to Lose a Ton of Money, Analyst Says

    Canadian marijuana producer Canopy Growth has loads of cash and an early start, as prohibitions fall around the world. But at $28 per share, Canopy stock is expensive, an analyst said.

  • MarketWatch

    Canopy Growth stock gains again; Oppenheimer initiates at 'perform' with no price target

    The U.S.-listed shares of Canopy Growth Corp. edged up 0.3% toward a fourth straight gain in midday trading Wednesday, although Oppenheimer analyst Rupesh Parikh initiated coverage of the Canada-based cannabis company with a not-so-enthusiastic "perform" rating and no price target. Parikh said that he believes Canopy is "best positioned" to capitalize on the global cannabis market over time, given its first-mover advantage, investments in key geographies, such as the U.S., Canada and Europe, partnership with Constellation Brands Inc. and the most capital of any cannabis player. "However, shorter-term, we believe a full valuation, lofty [Wall] Street expectations, the potential for losses to persist and regulatory delays hamper the case for outperformance," Parikh wrote in a note to clients. The regulatory delays refers to delays regarding use of CBD (cannabinoids) in the U.S. Of the 24 analysts surveyed by FactSet, nine have the equivalent of hold, 14 have the equivalent of buy and one has the equivalent of sell. The stock has now gained 5.9% year to date, while the ETFMG Alternative Harvest ETF has lost 4.7% and the S&P 500 has rallied 19.5%.

  • Canopy Growth Looks for CEO, Linton Gets a New Role
    Market Realist

    Canopy Growth Looks for CEO, Linton Gets a New Role

    Canopy Growth took the market by surprise and let CEO Bruce Linton go. After leaving Canopy Growth, Linton joined three companies in an advisory role.

  • Cronos Group Stock Continues to Lag as Canada Headwinds Hold Back Sector
    InvestorPlace

    Cronos Group Stock Continues to Lag as Canada Headwinds Hold Back Sector

    Cronos Group (NASDAQ:CRON) is not alone as its shares have fallen more than 33% since April 5. Compliance issues and regulatory delays in Canada, have also weighed on Tilray (NASDAQ:TLRY), Canopy Growth (NYSE:CGC) and Aurora Cannabis (NYSE:ACB). CRON stock, though, has fared the best of that bunch. Yet, despite the problems, you'd be hard-pressed to find a faster-growing industry than cannabis. According to recent research, the global market size is expected to reach $66.3 billion by the end of 2025, though these estimates vary widely. InvestorPlace - Stock Market News, Stock Advice & Trading TipsBut Wall Street still has mixed reactions when it comes to Cronos Group stock. Out of the 14 analysts reviewing the stock, eight have given it a hold rating. Here are a few reasons why analysts aren't more bullish about CRON stock. Cronos Delivered Mixed Q2 ResultsCRON stock hit a new 52-week low in early August, thanks in part to a mixed earnings report. Initially, the company's shares rose due to better-than-expected sales. But Cronos Group also saw its operating losses widen. And on the earnings call, company executives said they expect these losses to increase during the second half of the year. This is due to Cronos' investments in sales and marketing and other growth initiatives. * 10 Battered Tech Stocks to Buy Now As well, Cronos Group lags behind other cannabis companies in terms of production. While it produced nearly 1,600 kilos during the second quarter, that's less than one-fifth of the the 29,000 kilos Aurora Cannabis produced. Vaping Concerns Could Affect CRON StockCanadian cannabis companies are currently waiting on the second wave of cannabis legalization, set for the middle of next month. This will include a limited supply of items like vapes, cannabis-infused beverages, and edibles.But there is a growing concern in the U.S. about the safety of vaping. More than 450 Americans dealt with vaping-related lung illnesses and five of these patients died. It's unclear what's causing the illnesses but there does seem to be a link between THC-infused products and vaping. (My InvestorPlace colleague Josh Enomoto has a contrarian take on this today.) * 7 Momentum Stocks to Buy On the Dip In March, Cronos Group received an equity investment from the tobacco giant Altria Group (NYSE:MO). Altria also owns a stake in the e-cigarette makers Juul, which gives Cronos access to additional vaping technology. However, this could pose a problem is the health-related concerns continue to gain traction. Expect More Supply Issues in CanadaCanada continues to deal with ongoing supply issues since legalizing cannabis in October 2018. The regulatory agency Health Canada is dealing with a backlog of licensing applications.Most likely, Canada will still be dealing with this issues when cannabis derivatives hit the shelves in December. And it will continue to slow the ability of companies like CRON to harvest, process, and sell cannabis.As of this writing, Jamie Johnson did not hold a position in any of the aforementioned stocks. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 10 Recession-Resistant Services Stocks to Buy * 7 Hot Penny Stocks to Consider Now * 7 Tech Stocks You Should Avoid Now The post Cronos Group Stock Continues to Lag as Canada Headwinds Hold Back Sector appeared first on InvestorPlace.

  • TheStreet.com

    [video]Canopy Growth Initiated With Neutral Rating at Oppenheimer

    Canopy Growth is best positioned to capitalize on the cannabis revolution, according to a note from Oppenheimer analyst Rupesh Parikh, who initiated coverage of the stock with a "perform" rating, which is similar to a neutral rating. Parikh called Canopy Growth the company best positioned to capitalize on the global cannabis market over time, but he is tepid on the stock due to Wall Street's "lofty" expectations from the sector. "We expect CGC to capture more than its fair share of the $150B+ global opportunity longer-term.

  • Benzinga

    What To Know About Gage Cannabis, The Michigan Company That Just Named Bruce Linton As Executive Chairman

    Canopy Growth Corporation (NYSE: CGC) co-founder and former CEO Bruce Linton has made a big splash for his reemergence into the cannabis industry. In addition to becoming a special advisor to animal health and wellness CBD company Better Choice Company and an activist investor in Slang Worldwide, Linton has been named executive chairman of Michigan-based Gage Cannabis. Gage Cannabis has earned a reputation for promoting a "high-end marijuana experience." The company uses a small-batch approach to cultivation and processing in order to deliver high quality cannabis and cannabis products.

  • PR Newswire

    Canopy Growth Announces Election of Board of Directors

    SMITHS FALLS, ON , Sept. 17, 2019 /PRNewswire/ - Canopy Growth Corporation (TSX:WEED) (NYSE: CGC) ("Canopy Growth" or "the Corporation") today announced that all of management's nominees ...

  • Cannabis Roundup: IIPR, WEED, ACB, and APHA
    Market Realist

    Cannabis Roundup: IIPR, WEED, ACB, and APHA

    The markets were flat today as the Fed started its two-day meeting. Cannabis ETFs reported mixed performance, and cannabis stocks traded mostly in the red.

  • Aurora versus Canopy: A Post-Earnings Valuation Update
    Market Realist

    Aurora versus Canopy: A Post-Earnings Valuation Update

    On September 16, Aurora Cannabis was trading at 7.26 Canadian dollars. Its stock has fallen 14.7% since it reported its fiscal 2019 fourth-quarter results.

  • MarketWatch

    Better Choice's stock soars after former Canopy Growth co-CEO Bruce Linton appointed 'special advisor'

    Bruce Linton has resurfaced, as the high-profile former co-chief executive of Canopy Growth Corp. has been appointed "Special Advisor" to Florida-based Better Choice Co. Inc. , an animal health and wellness CBD company. Better Choice's stock soared 21% in morning trading, with volume of 65,000 shares already about 13-times the full-day average. Linton, who was fired from Canopy in July, will be working to help expand Better Choice's cannabinoid (CBD) animal research, build out an internal intellectual property, data and analytics platform and explore strategic alternatives and partnerships. "Better Choice is focused and has access to funding to deliver research-driven outcomes in the animal health and wellness industry, as the Company develops a data- and research-driven approach to product development and efficacy within the cannabinoids-as-ingredients space," Linton said. The stock has now lost 55% year to date, while the ETFMG Alternative Harvest ETF has slipped 1.0% and the S&P 500 has gained 20%.

  • CNW Group

    /R E P E A T -- Alan Cooke Joins EuroLife as Strategic Advisor Following Success at Canopy Growth/

    /R E P E A T -- Alan Cooke Joins EuroLife as Strategic Advisor Following Success at Canopy Growth/

  • Benzinga

    Bruce Linton Joins Cannabis Pet Market, Becomes Special Advisor To Better Choice Company

    Better Choice Company, Inc. (OTC: BTTR), an animal health and wellness CBD company, said Tuesday it has appointed co-founder and former CEO of Canopy Growth Corporation (NYSE: CGC) Bruce Linton as a special advisor. At Better Choice, Linton's duties will include working on broadening the company’s cannabinoid animal research, developing internal intellectual property, and investigating strategic and partnership opportunities. “I look forward to working closely with the Better Choice team to solidify its global expansion plans, identify other strategic opportunities that will increase shareholder value and expand my role at the Company in the future,” Linton said in a statement.

  • Wolverine Partners Corp. to Change Name to Gage Growth Corp. and Appoint Bruce Linton as Executive Chairman
    CNW Group

    Wolverine Partners Corp. to Change Name to Gage Growth Corp. and Appoint Bruce Linton as Executive Chairman

    Gage Cannabis Co.) (the "Company" or "Gage"), one of Michigan's leading craft cannabis and brand platforms, today announced the proposed change of its corporate name to Gage Growth Corp. and addition of Bruce Linton , who will be appointed to the role of Executive Chairman. The changes are expected to be made effective in connection with the closing of Gage's proposed acquisition of Rivers Innovations Inc. ("Innovations").

  • CNW Group

    /R E P E A T -- Santé Cannabis and Spectrum Therapeutics Launch Transformative Medical Cannabis Training Program for Québec Healthcare Professionals/

    MONTREAL and SMITHS FALLS, ON , Sept. 16, 2019 /CNW/ - Québec doctors have a new tool at their disposal for learning about medical cannabis and its viability as a treatment option for their patients. Santé Cannabis, a pioneer in medical cannabis in Québec, has partnered with Spectrum Therapeutics, the medical division of Canopy Growth (WEED.TO) (CGC) to launch the Prescriber Training Program, designed to aid physicians and patients, announced today at the new Santé Cannabis clinic and research centre in Montréal.

  • GlobeNewswire

    Bruce Linton Joins Better Choice Company as Special Advisor

    Better Choice Company, Inc. (BTTR) (the “Company” or “Better Choice”), a global animal health and wellness CBD company, today announced that it has appointed Bruce Linton, Founder of Canopy Growth Corporation (CGC), as a Special Advisor to the Company. Mr. Linton will be working with Better Choice to, among other things, (a) expand the Company’s global cannabinoid animal research, (b) build out an internal intellectual property, data and analytics platform and (c) explore strategic initiatives and partnerships for the business.

  • CNW Group

    Alan Cooke Joins EuroLife as Strategic Advisor Following Success at Canopy Growth

    Alan Cooke Joins EuroLife as Strategic Advisor Following Success at Canopy Growth

  • Cannabis Roundup: MMEN, ACB, WEED, and CTST
    Market Realist

    Cannabis Roundup: MMEN, ACB, WEED, and CTST

    Today at 2:10 PM ET, the S&P; 500 Index fell 0.3% as investors watched rising oil prices. The cannabis sector also fell today, as its ETFs traded in the red.

  • Benzinga

    Podcast: The Evolution Of Cannabis Legalization With Benzinga's Javier Hasse

    Podcast via Kannaboomers . “ This is a social movement that is moving forward faster than any other social movement in the world and probably in history. “ — Javier Hasse History is being made, day by ...

  • Benzinga

    Stifel: Aurora's 'Bad' Q4 Extends Beyond Headline Numbers

    Aurora's shortfall in the quarter is evident due to a reported $20.1 million of bulk wholesale trim sales that are unlikely to repeat at the same level, Carter said in a Sunday downgrade note. The headline net cannabis revenue of CA$94.7 million suggests a net cannabis revenue base closer to CA$75 million versus Stifel's estimate of CA$92.5 million.

  • Cronos Group: Target Price and Valuation Update
    Market Realist

    Cronos Group: Target Price and Valuation Update

    The consensus target price for Cronos Group stock fell to 19.88 Canadian dollars from 20.3 Canadian dollars in August, which represents a fall of ~2.07%.

  • CNW Group

    Santé Cannabis and Spectrum Therapeutics Launch Transformative Medical Cannabis Training Program for Québec Healthcare Professionals

    MONTREAL and SMITHS FALLS, ON , Sept. 16, 2019 /CNW/ - Québec doctors have a new tool at their disposal for learning about medical cannabis and its viability as a treatment option for their patients. Santé Cannabis, a pioneer in medical cannabis in Québec, has partnered with Spectrum Therapeutics, the medical division of Canopy Growth (WEED.TO) (CGC) to launch the Prescriber Training Program, designed to aid physicians and patients, announced today at the new Santé Cannabis clinic and research centre in Montréal.

  • Wall Street's first cannabis analyst names her top US marijuana stocks
    Yahoo Finance

    Wall Street's first cannabis analyst names her top US marijuana stocks

    Cowen analyst Vivian Azer just crowned a new U.S. cannabis company with her strongest conviction Outperform.

  • Benzinga

    The Week In Cannabis: Big Pharma Makes Moves, Diddy & Wahlberg Go After CBD, Medicine Man Continues M&A Spree

    This week, we saw Teva Pharmaceutical Industries Ltd (NYSE: TEVA ) make a big move in the cannabis industry, through a distribution deal between its subsidiary Salomon, Levin, Elstein, and InterCure Ltd ...